

OFFICIALLY LICENSED
BEST OF ASCO[®]
2018 ANNUAL MEETING

event in Greece

A program licensed by the American Society of Clinical Oncology

September 21-22 2018 | Crown Plaza Hotel | Athens



Θα χορηγηθούν μόρια
Συνεχιζόμενης
Ιατρικής Εκπαίδευσης
(CME - CPD credits)
ΔΗΛΩΣΕΙΣ ΣΥΜΜΕΤΟΧΗΣ
ΣΤΟ info@scep.gr

Organizers
ΕΡΕ.Ι.Κ.
RESEARCH & TRAINING INSTITUTE
OF CLINICAL ONCOLOGY

with the scientific collaboration of



scientific program



Επιστημονικό Πρόγραμμα

Friday, September 21st, 2018

11.50-12.00 **Welcome and Chair Remarks**

V. Georgoulas

12.00-13.30 **Session 1: Breast Cancer**

Chairpersons: **D. Tryfonopoulos, M. Nikolaou**

12.00-12.15 Presenter: **S. Kokkali**

- Abstract ID: 506
Title: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results
- Abstract ID: 500
Title: Adjuvantdenosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial

12.15-12.30 Presenter: **S. Peroukidis**

- Abstract ID: LBA1
Title: TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node negative breast cancer and an intermediate prognosis 21-gene recurrence score
- Abstract ID: 1000
Title: Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3

12.30-12.45 Presenter: **F. Stavridi**

- Abstract ID: 104
Title: Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).
- Abstract ID: 1005
Title: Everolimus (EVE) + Exemestane (EXE) vs EVE Alone or Capecitabine (CAP) for Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2-negative (HER2-) Advanced Breast Cancer (ABC): BOLERO-6, an Open-label Phase 2 Study

12.45-13.00 Presenter: **E. Moirogiorgou**

- Abstract ID: LBA1006
Title: Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER

- Abstract ID: 1007

Title: AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial

13.00-13.20 Discussant: **D. Tryfonopoulos**

13.20-13.30 Discussion

13.30-14.00 **Educational Session: Personalized Care in the Management of Kidney Cancer**

Chairpersons: **G. Samonis, V. Georgoulas**
Presenter: **M. Tsiatas**

14.00-15.00 **Light lunch**

15.00-16.00 **Session 2: Malignant Melanoma**

Chairpersons: **D. Bafaloukos, K. Kalbakis**

15.00-15.15 Presenter: **A. Laskarakis**

- Abstract ID: 108
Title: Epacadostat plus pembrolizumab versus pembrolizumab alone in patients with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.
- Abstract ID: 9501
Title: Final analysis of DECOG-SLT trial: No survival benefit for complete lymph node dissection in melanoma patients with positive sentinel node

15.15 -15.30 Presenter: **P. Economopoulou**

- Abstract ID: 9502
Title: Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238)
- Abstract ID: 9504
Title: Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vsVemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma

15.30-15.50 Discussant: **D. Bafaloukos**

15.50-16.00 Discussion

16.00-17.00 **Session 3: Genitourinary Cancer (Non-Prostate cancer)**

Chairpersons: **A. Nikolaidi, M. Tsiatas**

16.00-16.15 Presenter: **G. Lainakis**

- Abstract ID: 4500
Title: Pembrolizumabmonotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427



- Abstract ID: 4511
Title: Patient-reported outcomes (PROs) in IMmotion151: atezolizumab (atezo) + bevacizumab (bev) vssunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC)

16.15-16.30 Presenter: **E. Lianos**

- Abstract ID: LBA3
Title: CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma - Results of a phase III noninferiority trial
- Abstract ID: 4503
Title: First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt)

16.30-16.50 Discussant: **K. Koutsoukos**

16.50-17.00 Discussion

17.00-17.30 **Coffee Break**

17.30-18.30 **Session 4: Gastrointestinal (Colorectal) Cancer**

Chairpersons: **N. Ziras, P. Papakostas**

17.30-17.45 Presenter: **V. Michalaki**

- Abstract ID: 3505
Title: First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study
- Abstract ID: 3500
Title: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6

17.45-18.00 Presenter: **N. Tsoukalas**

- Abstract ID: 3501
Title: Long-term results of the ADORE trial: adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer
- Abstract ID: LBA 3503
Title: A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7

18.00-18.20 Discussant: **G. Papaxoinis**

18.20-18.30 Discussion

18.30-19.30 **Session 5: Gastrointestinal (Non-Colorectal) Cancer**

Chairpersons: **N. Kentepozidis, O. Katopodis**

18.30-18.45 Presenter: **T. Bilidas**

- Abstract ID: LBA4001
Title: Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized controlled phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas
- Abstract ID: 4004
Title: A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211)

18.45-19.00 Presenter: **A. Ntokou**

- Abstract ID: LBA4008
Title: Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial
- Abstract ID: LBA4002
Title: Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial

19.00 – 19.20 Discussant: **A. Karampeazis**

19.20 – 19.30 Discussion

Saturday, September 22nd, 2018

09.00-10.30 **Session 6: Lung Cancer (1)**

Chairpersons: **P. Kosmidis, A. Koutsopoulos**

09.00-09.15 Presenter: **M. Bakogeorgos**

- Abstract ID: 8503
Title: DREAM: A Phase II study of DuRvalumab with first line chemotherapy in Mesothelioma: First Results
- Abstract ID: 8506
Title: Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158

09.15-09.30 Presenter: **K. Rapti**

- Abstract ID: 8507
Title: Efficacy and safety of rovalpituzumabtesirine in patients With DLL3-expressing, ≥ 3rd line small cell lung cancer: results from the Phase 2 TRINITY study



- Abstract ID: LBA9000
Title: IMpower131: Primary PFS and Safety Analysis of a Randomized Phase III Study of Atezolizumab + Carboplatin + Paclitaxel or Nab-Paclitaxel vs Carboplatin + nab-Paclitaxel as 1L Therapy in Advanced Squamous NSCLC

09.30-09.45 Presenter: **Th. Tegos**

- Abstract ID: 9001
Title: Nivolumab (nivo) + ipilimumab (ipi) vs chemotherapy as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): additional endpoints from the randomized phase 3 CheckMate 227 study
- Abstract ID: 9006
Title: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations. NEJ026
- Abstract ID: LBA4
Title: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) $\geq 1\%$: Open-label, phase 3 KEYNOTE-042 study

09.45-10.00 Presenter: **E. Res**

- Abstract ID: 8502
Title: Pragmatic Study of a Lymph Node (LN) Collection Kit for Non-Small Cell Lung Cancer (NSCLC) Resection.
- Abstract ID: 105
Title: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel with pembrolizumab or placebo for patients with metastatic squamous non-small cell lung cancer (NSCLC)

10.00-10.20 Discussant: **N. Katirtzoglou**

10.20-10.30 Discussion

10.30-11.30 **Session 7: Genitourinary Cancer (Prostate cancer)**

Chairpersons: **Ch. Kourousis, D. Matthaios**

10.30-10.45 Presenter: **F. Koinis**

- Abstract ID: 5000
Title: A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial
- Abstract ID: 5001
Title: Ga-PSMA11 PET/CT localizes recurrent prostate cancer with high accuracy: Preliminary results from a phase 2/3 prospective trial

10.45-11.00 Presenter: **A. Koulouris**

- Abstract ID: 5003
Title: Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized Phase II trial
- Abstract ID: 5007
Title: KEYNOTE-199: pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC)

11.00-11.20 Discussant: **Z. Zafeiriou**

11.20-11.30 Discussion

11.30-12.00 **Coffee Break**

12.00-13.15 **Session 8: Development Therapeutics – Clinical Pharmacology / Tumor Biology**
Chairpersons: **F. Zagouri, F. Papageorgiou**

12.00-12.15 Presenter: **N. Volakakis**

- Abstract ID: 102
Title: A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers
- Abstract ID: 3000
Title: :ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers

12.15-12.30 Presenter: **E. Kontopodis**

- Abstract ID: 3003
Title: Durability of Response in ZUMA-1, the Pivotal Phase 2 Study of AxicabtageneCiloleucl (Axi-Cel) in Patients (Pts) With Refractory Large B Cell Lymphoma
- Abstract ID: 3006
Title: NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT

12.30-12.45 Presenter: **K. Stouraiti**

- Abstract ID: 12000
Title: Association of high tissue TMB and atezolizumab efficacy across multiple tumor types
- Abstract ID: 12001
Title: Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results

12.45-13.05 Discussant: **C. Emmanouilides**

13.05-13.15 Discussion



13.15-14.15 **Light lunch**

14.15-15.15 **Session 9: Head and Neck Cancer**

Chairpersons: **Ch. Panopoulos, D. Moraitis**
Presenter: **A. Tzovaras**

- 14.15-14.30 - Abstract ID: 6000
Title: Results of a randomized phase III study of Nimotuzumab in combination with concurrent radiotherapy and Cisplatin versus radiotherapy and Cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck
- Abstract ID:6006
Title: Results of a randomized, placebo (PBO) controlled, double-blind P2b trial of GC4419 (avisopasem manganese) to reduce duration, incidence and severity and delay onset of severe radiation-related oral mucositis (SOM) in patients (pts) with locally advanced squamous cell cancer of the oral cavity (OC) or oropharynx (OP)

14.30-14.45 Presenter 2: **P. Katsaounis**

- Abstract ID: 6008
Title: Multicenter Phase II Trial of Palbociclib, a Selective Cyclin Dependent Kinase (CDK) 4/6 Inhibitor, and Cetuximab in Platinum-Resistant HPV Unrelated (-) Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)
- Abstract ID: 6009
Title: A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC)

14.45-15.05 Discussant: **A. Argiris**

15.05-15.15 Discussion

15.15-16.15 **Session 10: Sarcomas**

Chairpersons: **D. Tzanninis, V. Ramfidis**

15.15-15.30 Presenter: **J. Duran Moreno**

- Abstract ID: 11506
Title: Randomized comparison of pazopanib (PAZ) and doxorubicin (DOX) in the first line treatment of metastatic soft tissue sarcoma (STS) in elderly patients (pts): Results of a phase II study (EPAZ)
- Abstract ID: 11503
Title: Anlotinib for metastasis soft tissue sarcoma: A randomized, doubleblind, placebo-controlled and multi-centered clinical trial

15.30-15.45 Presenter: **I. Alafis**

- Abstract ID: 11507
Title: Randomized phase II trial of trofosfamide vs. adriamycin in elderly patients with previously untreated metastatic soft tissue sarcoma

- Abstract ID: 11508
Title: Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial

15.45-16.05 Discussant: **S. Kokkali**

16.05-16.15 Discussion

16.15-16.30 **Coffee Break**

16.30-17.30 **Session 11: Gynecological Cancer**

Chairpersons: **E. Terzakis, D. Trafalis**

16.30-16.45 Presenter: **S. Stamatopoulou**

- Abstract ID: 5500
Title: Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602

- Abstract ID: 5505

- Title: Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study

16.45-17.00 Presenter: **I. Syrios**

- Abstract ID: 5506

- Title: Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17

- Abstract ID: 5508

- Title: Cost-Effectiveness of Maintenance Therapy in Advanced Ovarian Cancer: Paclitaxel, Bevacizumab, Niraparib, Rucaparib, Olaparib, and Pembrolizumab

17.00-17.20 Discussant: **Ch. Kourousis**

17.20-17.30 Discussion

17.30-18.00 **Educational Session: Rational Combinations With an Immuno-Oncology Backbone**

Chairpersons: **K. Baxevanis, V. Georgoulas**

Presenter: **N. Pistalmatzian**

18.00-18.20 General Discussion

18.20-18.45 **Closing Remarks**



Scientific | Cultural Events and Publications

T +30 210 7240039, +30 2810 222155 F +30 210 7240139, +30 2810 222156

E info@scep.gr www.scep.gr